share_log

HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Lowers Price Target to $18

Benzinga ·  Aug 12, 2024 17:52  · Ratings

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and lowers the price target from $19 to $18.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment